Business Context and Reporting Period
Company: Research Frontiers Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 18, 2026
Principal Business: The Company is engaged in the development and licensing of SPD-SmartGlass products, including applications for the retrofit architectural glass market.
Key Financial Metrics and Transaction Details
This filing reports a specific capital raise event rather than periodic financial performance metrics (revenue, profit, cash flow, or margins are not disclosed in this document).
- Transaction Type: Private placement of common stock and warrants.
- Shares Issued: 1.1 million shares of common stock.
- Price Per Share: $1.00 (based on the closing market price on February 13, 2026).
- Total Proceeds: $1.1 million.
- Warrant Terms: One warrant per share issued, expiring February 28, 2031. Exercise prices are tiered: $1.10 (through Feb 2027), $1.20 (through Feb 2028), $1.30 (through Feb 2029), and $1.50 (thereafter).
- Investor Profile: A group of private accredited investors, including family members of a director and the owner of a licensee.
Material Changes Versus Prior Period
The filing does not provide comparative financial data or year-over-year changes in revenue or operating metrics. The material change reported is the increase in equity capital and the issuance of new warrants as of February 18, 2026.
Guidance, Outlook, Risks, and Unusual Items
Forward-Looking Statements: The filing contains standard forward-looking statements regarding economic conditions, industry environments, and company performance. Management explicitly states no obligation to update these projections.
Risks and Contingencies:
- Market Risks: Results could be affected by sales performance, expense levels, competitive activity, and interest rates.
- Liquidity Constraints: The newly issued shares and any shares from future warrant exercises are unregistered and subject to a minimum six-month holding period for investors.
Unusual Items: The transaction involved related parties (family members of a director) and a strategic licensee, which may present specific governance or conflict of interest considerations.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the use of the $1.1 million in proceeds as disclosed in subsequent filings.
- Review the specific terms of the "licensee" relationship mentioned to understand strategic alignment.
- Monitor the six-month holding period expiration for the new shares to gauge future selling pressure.
- Check subsequent 10-Q or 10-K filings for updated revenue and cash flow data not present in this 8-K.